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Abstract
Background: HSP90 may be a favorable target for investigational therapy in breast cancer. In fact, the HSP90
inhibitor, 17AAG, currently has entered in phase II clinical trials as an anticancer agent in breast and other tumors.
Since HSP90 inhibition leads to global depletion of oncogenic proteins involved in multiple pathways we applied
global analysis using gene array technology to study new genes and pathways involved in the drug response in
breast cancer.
Methods: Gene expression profiling using Whole Human Genome Agilent array technology was applied to a total
of six sensitive and two resistant breast cancer cell lines pre-treatment and treated with the 17AAG for 24 and 48
hours.
Results: We have identified a common molecular signature of response to 17AAG composed of 35 genes which
include novel pharmacodynamic markers of this drug. In addition, different patterns of HSP90 client transcriptional
changes after 17AAG were identified associated to the sensitive cell lines, which could be useful to evaluate drug
effectiveness. Finally, we have found differentially expressed pathways associated to resistance to 17AAG. We
observed significant activation of NF-B and MAPK pathways in resistant cells upon treatment, indicating that
these pathways could be potentially targeted to overcome resistance.
Conclusions: Our study shows that global mRNA expression analysis is a useful strategy to examine molecular
effects of drugs, which allowed us the discovery of new biomarkers of 17AAG activity and provided more insights
into the complex mechanism of 17AAG resistance.
Background
Considering the complexity of breast cancer, with its
multiple genetic abnormalities, targeting a single path-
way by inhibiting the activity of one component is unli-
kely to be effective in a long term. Identification of
molecular targets that will modulate multiple compo-
nents of several signalling pathways would be desired
for anticancer treatment. To that end, HSP90 gained
lately extreme interest and became an interesting cancer
drug target [1]. In breast cancer, preclinical studies have
demonstrated sensitivity of HER2
+ tumors to HSP90
inhibitor [2-4], lately though it was demonstrated that
HSP90 is a very effective target of therapy in triple
negative breast cancers [5,6]. HSP90 is a chaperone for
several oncogenic client proteins (ERBB2, B-RAF,
CDK4, AKT, mutant p53, among others) involved in
transcriptional regulation, signal transduction, and cell
cycle control as well as in other crucial steps leading to
malignant phenotype [7,8]. Hsp90 is overexpressed in
tumor cells, indicating that these cells are highly depen-
dent on the Hsp90 function [9]. Mutant oncoproteins
may depend on the full function of Hsp90 as a confor-
mational buffer to maintain full activity [10-13].
The HSP90 inhibitor, 17-allyloamino-17-demethoxy-
geldanamycin (17AAG) a geldanamycin analogue, is cur-
rently in phase II clinical trials [14] in a number of can-
cers [15-19], see http://www.clinicaltrials.gov. At
present, most of the drug candidates fail relatively late
during the process (phase III) of clinical trials due to
lack of efficacy [20,21]. To save that failure there is a
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with great specificity, indicate the presence or absence
of the desired pharmacological response[22]. Since
HSP90 inhibition leads to global depletion of oncogenic
proteins involved in multiple signaling pathways, expres-
sion signatures have been developed to understand the
mechanisms of drug action and to predict the sensitivity
to treatment. With the microarray technology, rather
than studying effect of the drug on a single gene or pro-
tein, we can now look for signatures consisting of multi-
ple genes that are altered in some way, and together
define novel set of pharmacodynamic biomarkers of the
drug response as well as of resistance[23]. Gene expres-
sion and proteomic profiling studies have been done
previously in a panel of ovarian and colon cancer cell
lines after 17AAG treatment [24,25] and in pancreatic
cancer after treatment with 17AAG partner, IPI 504
[26], however there are no previous studies focused in
breast tumors under 17AAG treatment.
Although a basic molecular signature of response to
17AAG has been previously defined [27] with depletion
of the levels of client proteins such as c-RAF-1 and
cyclin-dependant kinase 4 (CDK4), and upregulation of
the inducible isoform of HSP70 (HSP72), the exact
mechanism of action of 17AAG has not been clearly
defined. To that end a discovery of clinical markers of
response and mechanism of resistance to 17AAG are
still a matter of time. The need to reveal biomarkers
and understand the resistance will help to identify
responsive versus non responsive patients to 17AAG. In
our current study we performed a global gene expres-
sion analysis using Whole Human Genome array tech-
nology to understand the molecular mechanism of
action of 17AAG in breast cancer. First, we have identi-
fied a breast cancer signature of response to 17AAG
and suggested biomarkers of 17AAG sensitivity in breast
cancer. Secondly, we have studied transcriptional
changes in known HSP90 clients. And finally, we have
identified gene expression and pathway activity differ-
ences in response to 17AAG in sensitive versus resistant
cell lines.
All together these results may provide further under-
standing of the mode of action of 17AAG and suggest
potential molecular markers of response and drug resis-
tance in breast cancer.
Methods
Breast Cancer cell lines
Eight breast cancer cell lines were included in this study,
MCF-7, MDA-MB-157, Hs578T, HCC1937, MDA-MB-
436, UACC3199, MDA-MB-231 and T47D). Breast can-
cer cell lines, MCF-7, UACC3199, Hs578T, MDA-MB-
2 3 1a n dT 4 7Dw e r eo b t a i n e df r o mC a n c e rE p i g e n e t i c
Group at Spanish National Cancer Centre, Madrid,
Spain. HCC1937 and MDA-MB-157 were kindly pro-
vided by Dr. P. Edwards from Department of Pathology,
University of Cambridge, Cambridge, UK and MDA-
MB-436 by Dr. K.S Massey-Brown from Department of
Pharmacology and Toxicology, University of Arizona,
Tucson, USA. These tumor cell lines were cultured in
RPMI 1640 containing 10% fetal bovine serum (Gibco-
BRL, Grand Island, NY, USA) with the exception of
MDA-MB-157 being cultured in DMEM/F12 (Gibco-
BRL) supplemented with 10% fetal bovine serum and
maintained at 37°C in 5% CO2. All media were supple-
mented with fungizone, and penicillin/streptomycin.
Fresh material from a tumor biopsy corresponding to
a breast tumor sample was used to validate results
obtained in cell lines. Appropriate ethical committee
approval and informed consent was obtained. Tumor
was cultured in vitro, and after several passages, tumor
cells were treated with 17AAG at the same dose used
for the cell lines. These primary tumor cells were grown
in F-10 medium (Gibco), supplemented with 10% fetal
bovine serum and 2% Ultroser G (PALL Life Sciences).
Drug and treatment protocol
17AAG (Sigma-Aldrich, St.Louis, MO, USA) was pre-
pared as a 1 mM stock in dimethyl sulfoxide (DMSO)
a n ds t o r e da t- 2 0 ° Ca n df r e s h l yd i s s o l v e di m m e d i a t e l y
prior to use. Cells were seeded in 10 cm dishes at a
moderate density in 20 ml complete medium. At 24 h
after plating, cells were treated with 500 nM 17AAG or
DMSO (0.1%) as a control. At appropriate intervals 24
H, 48 H upon treatment with the drug, cells were
harvested.
RNA extraction, cRNA amplification, labeling and
hybridization
Total RNA was extracted with TriReagent (Molecular
Research Center, Cincinnati, OH, USA). Purity and
integrity of the RNA was assessed with Agilent 2100
BioAnalyzer (Agilent Technologies, Palo Alto, CA,
USA). Then, 500 ng of total RNA from samples and
Universal Human Reference RNA (Stratagene, La Jolla,
CA, USA) were used for amplification and labeling
using the Agilent’s Low RNA Input Linear Amplification
Kit (Agilent Technologies) following the detailed proto-
col described in the kit manual. Cyanine 5 labeled sam-
ples or Cyanine 3 labeled reference cRNAs were purified
using QIAGEN’s RNeasy mini spin columns and eluted
in 30 μl of nuclease-free water. After amplification and
labeling, cRNA quantity and cyanine incorporation were
determined using a nanodrop ND.1000 UV-VIS-Spec-
trophotometer version 3.2.1 (Agilent Technologies). For
each hybridization,1 μg Cyanine 3 labeled cRNA (refer-
ence) and 1 μg of Cyanine 5 labeled cRNA (samples)
were mixed, fragmented, and hybridized at 65°C for 17
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Oligo Microarray containing 45,015 features represent-
ing 41,000 unique probes. We have hybridized each
sample at each time point (untreated, treated 24 H and
48 H with 17AAG), including some technical replicates.
After washing, microarrays were scanned using an Agi-
lent Array scanner (Agilent Technologies). Images were
analyzed. Reproducibility and reliability of each single
microarray was assessed using Quality Control report
data. Data were extracted with Agilent feature extraction
software (version 9.5.3) using the GE2-v5_95_Feb07 pro-
tocol. Background substraction were carried out using
normexp. Lowess and quantiles methods were per-
formed for intra-array and inter-array normalization
respectively. Expression ratios were calculated (Cy5 pro-
cessed signal was divided by Cy3 processed signal) and
log2 transformed. Gene patterns containing missing
values were discarded. Additionally a filter procedure
eliminated genes with uniformly low expression or with
low expression variation across the experiments, retain-
ing 20374 genes and transcripts. Microarray dataset is
publicly available at GEO database http://www.ncbi.nlm.
nih.gov/geo/info/linking.html (GEO accession number,
GSE23209).
Differential gene expression analysis
To determine if there were genes differentially expressed
between treated and untreated and sensitive versus resis-
tant breast cancer cell lines supervised classification was
performed with linear models (limma) implemented in
the POMELO II tool, available in Asterias web server
http://asterias.bioinfo.cnio.es. The estimated significance
level (p value) was corrected for multiple hypotheses test-
ing using Benjamini & Hochberg [28] False Discovery
Rate (FDR) adjustment. Those genes with FDR <0.05
were selected as significantly differentially expressed.
Clustering
Average linkage hierarchical clustering (Pearson correla-
tion, uncentered metrics) from Gene Cluster and Tree-
view http://rana.stanford.edu/software algorithms were
used to obtain clustering of the data sets. The level of
expression of each gene in each sample, relative to the
median level of expression of that gene across all the
samples is represented using a red-white-blue color
scale. Blue correspond to expression value below med-
ian, white, equal to median and red above the median.
Functional Profiling of genes and pathways
We used Gene Set Enrichment Analysis (GSEA) to gain
insight into global molecular networks and canonical
pathways related to differentially expressed genes asso-
ciated to resistant phenotype after 17AAG treatment. In
o u rd a t aa n a l y s i sw eh a v ei n c l u d e dt h eB i o c a r t ah t t p : / /
www.biocarta.com as a source of pathway annotation,
and whichgenes web-based tool for building 249 gene
sets with application in gene set enrichment analysis
[29]. The ranking of genes was performed with T test,
with an absolute mode for gene list sorting. Gene set
permutations were used to assess the statistical signifi-
cance of the pathways. Those pathways showing FDR
<0.05, a well-established cut-off for the identification of
biologically relevant gene sets [30], were considered sig-
nificantly enriched between classes under comparison.
The ranking of genes was performed with T test, with
an absolute mode for gene list sorting.
Validation of microarray data by quantitative RT-PCR
analysis
One μg of total RNA was reverse transcribed using
MMLV Reverse Transcriptase (Invitrogen, San Diego,
CA, USA) and random primers. The cDNAs were sub-
jected to quantitative real-time PCR (QT-PCR) assay
with the use of labeled probes for selected genes (Roche
Universal Probe library, Basel, Switzerland) and the Taq-
Man Universal PCR Mix in an ABI prism 7900 system
(Applied Biosystems Inc, Foster City, CA, USA) under
manufacturer’s recommendations. The PCR amplifica-
tion was carried out with 10 min at 95°C, followed by
50 cycles of 15 s at 95°C and 1 min at 60°C, using the
oligonucleotides shown in Additional file 1: Supplemen-
tal Table S1. All experiments were analyzed in triplicate.
Validation of microarray data by western blot analysis
The protein expression changes were examined after 24
H and 48 H of 17AAG treatment. Western blot analysis
was performed using standard procedures for whole-cell
extracts from cell lines as described previously [31]. A
set of antibodies used for immunodetection are listed in
the Additional file 1: Supplemental Table S2. The
immunoblotting was repeated at least twice in all of the
experiments presented in this study.
Validation of microarray data by cell based multi-pathway
activity assays
Cignal Reporter Assay was performed according to man-
ufacturer’s instructions. Briefly, the transcription factor-
responsive reporter, negative control, and positive con-
trol constructs were diluted in Opti-MEM (Invitrogen).
The diluted nucleic acids were mixed with the diluted
SureFECTTM (transfection reagent; SABiosciences) and
delivered to 20,000 cells in a 96-well plate format. Cul-
ture media were changed 24 H after transfection. Trans-
fection efficiency was estimated by following the
expression of GFP (in the positive control wells) using
fluorescence microscopy. At 24 H post transfection
the cells were treated with the drug. After 48 H
of treatment, cells were harvested into cell lysis buffer
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the Dual-Luciferase Assay System (Promega) and a mul-
tilabel reader (Promega). The Firefly/Renilla activity
ratio generated from the transcription factor-responsive
reporter transfections was divided by the Firefly/Renilla
activity ratio generated from the negative control trans-
fections to obtain the relative luciferase units. At least
three independent transfections were carried out in tri-
plicate for each of the conditions tested with each
reporter assay. This experimental design was repeated at
least once.
Statistical analyses
Analyses of pathway activity differences upon treatment
in the resistant and sensitive cell lines were performed
using SPSS version 17.0 (SPSS Inc, Chicago, IL). Non-
parametric, Mann-Whitney U test was used for our sta-
tistical hypothesis testing. P-values reported are two-
sided.
Results
Identification of a molecular signature of response to
17AAG
Previous studies have shown feasibility of differential
gene expression approach to create expression-based
signatures predicting response or resistance in human
tumors to therapeutic agents. Here, we investigated the
biology underlying the differential gene expression
across breast cancer cell lines treated with HSP90 inhi-
bitor, 17AAG.
A total of eight breast cancer cell lines were analyzed.
In a previous study, six of them (MCF-7, MDA-MB-157,
Hs578T, HCC1937, MDA-MB-436, and UACC3199)
were demonstrated to be sensitive to treatment with
1 7 A A Gi nad o s ea n dt i m ed e p e n d e n tm a n n e rw i t h
IC50 values between 0.014 ± 0.006 μM and 0.059 ±
0.017 μM at 96 h [31]. In addition, two other cell lines
were also analyzed (MDA-MB-231, T47D) and found to
be resistant to 17AAG, showing IC50 values of 1.92 ±
0.4 μM and 3.82 ± 0.97 μM, respectively. Then, all cell
lines were treated with 500 nM 17AAG for 24 and 48
hours, concentration at which sensitive cells showed
cytotoxic and cytostatic effects as well as G2/M arrest
and degradation of client proteins [31], and whole gen-
ome expression profiling of control and treated cells at
this time points were performed.
Unsupervised hierarchical clustering of all samples
using more than 20000 genes, as expected, did not sepa-
rate the treated versus untreated cell lines. Instead, all
17AAG treated cell populations clustered with its con-
trol cell line, suggesting thatt h ee f f e c to ft h ed r u gi s
very subtle in the whole genome context or that the
effect of the drug is largely specific for each cell line
(Additional file 1: Supplemental Figure S1). In general,
after treatment with 17AAG, there was an increase in
the number of genes with expression changes >2-fold
over control cells after 48 h than after 24 h. Roughly,
the proportion of genes with >2-fold changes at 48 h
ranged between 8% and 35% in sensitive cells. Resistant
cell lines showed lower number of genes, only 2%
(MBA-MD-231) and 2.8% (T47D) of genes showing >2-
fold change versus control (Figure 1). Significantly, only
a small number of genes were commonly altered in the
resistant cell lines after treatment.
Figure 1 Gene expression changes induced by 17AAG. Averaged number of genes with expression changes >2-fold following 17AAG
treatment are represented for all breast cancer cell lines, at both time points 24 H and 48 H. Resistant cell lines MDA-MB-231 and T47 D
exhibited much lower variation after treatment.
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line, we searched for genes commonly associated to sen-
sitivity to 17AAG. Analysis of differentially expressed
genes between all treated compared with all untreated
17AAG sensitive breast cancer cell lines was performed.
A list of 35 genes with a significant FDR value <0.05
was obtained, which constituted a molecular signature
of response to 17AAG in breast cancer cells (Figure
2A). Among the 35 genes, 15 were down-regulated and
20 up-regulated genes following treatment (Table 1).
The up-regulated genes following treatment included
heat shock family proteins such as HSP90AA1, HSPA8,
DNAJB12, HSPA1L, DNAJA1, HSPA4L, consistently with
other array studies in different tumor cell types
[24,32,33]. Among other genes showing increased
expression after treatment were ubiquitin-conjugating
enzyme E2C (UBE2C), death effector domain containing
2( DEDD2), zinc finger protein 587 (ZNF587), zinc fin-
ger protein 473 (ZNF473), Rac GTPase activating pro-
tein 1 (RACGAP1), MHC class I polypeptide-related
sequence B (MICB), regulator of G-protein signalling 2
(RGS2), cysteine and histidine-rich domain (CHORD)-
containing 1 (CHORDC1), PPAR binding protein. There
were also down-regulated genes in response to 17AAG
which included e.g. JUNB, CYCLIN D1, NFKBIA,
immediate early response 3 (IER3), transmembrane pro-
tein 129 (TMEM129) or replication factor C (activator
1) 4 (RFC4).
As expected, most of the 35 genes from the signature of
response did not change upon treatment in the resistant
cell lines. However, some members of the co-chaperone
complex such as, HSP90AA1, HSPA4L, HSPA8, DNAJA1
and CHORDC1 showed induction following treatment, in
the resistant MDA-MB-231 cell line, but not in T47 D
cells (Figure 2B). Interestingly, HSP90 and HSP70 induc-
tion are common markers of response to 17AAG. Indeed,
HSP70 is one of the most commonly used pharmacody-
namic markers of HSP90 inhibition in clinical trials
nowadays. However, we have seen induction of the most
common isoforms of HSP70, HSPA8 (HSC70) and
Figure 2 Gene signature of response to 17AAG in breast cancer cell lines. A) Heat-map represents the expression of significant differentially
expressed 35 genes included in the molecular signature of response to 17AAG. Untreated samples were compared to treated samples from all
sensitive cell lines to obtain common variations. B) Comparison between the changes in expression in the genes included in the signature in
sensitive and resistant cells. Fold changes after 17AAG for sensitive cell lines, taken the averaged expression of all of them, compared to fold
changes in resistant MDA-MB-231 cells or T47 D.Error bars represent standard deviation. C) Western blot analysis of different HSP70 isoforms
before and after 17AAG in resistant MDA-MB-231 and sensitive MCF-7 cell line showed differential HSP70 induction after 17AAG. Lack of
induction of the HSPA2 and HSPA1L in resistant cells, and increased expression of HSP72 and HSC70 in both resistant and sensitive cell lines
upon treatment is shown. GAPDH was used as loading control.
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MB-231 resistant cell line. The induction of HSP90,
HSPA8 (HSC70) and HSP72 in MDA-MB-231 cells was
confirmed by QT-PCR and western blot (Figure 2C). We
also analyzed by western blot other isoforms of HSP70,
such as HSPA1L, which was part of the signature of
response, and HSPA2 (Figure 2C). These two isoforms,
in contrary to HSC70 and HSP72 were found exclusively
induced in responsive cell lines upon treatment, suggest-
ing that they could be better markers of sensitivity to
17AAG. Moreover, down or up-regulation of other dif-
ferentially expressed genes from the molecular signature
of response to 17AAG was also validated by QT-PCR
(Additional file 1: Supplemental Figure S2).
Table 1 Molecular signature of 17AAG response in breast cancer
20 Genes up-regulated following 17AAG treatment
Gene name Description FDR Fold Change
CHORDC1 Cysteine and histidine-rich domain (CHORD)-containing 1 (CHORDC1) 0.011 3.9
DEDD2 Death effector domain containing 2 (DEDD2) 0.011 2.2
HSPA8 Heat shock 70kDa protein 8 (HSPA8) transcript variant 1 0.011 4.6
NUDT9 Nudix (nucleoside diphosphate linked moiety X)-type motif 9 (NUDT9). transcript variant 1 0.011 2.4
PRDM11 PR domain containing 11 (PRDM11) 0.011 2.8
UBE2C Ubiquitin-conjugating enzyme E2C (UBE2C) 0.011 2.4
ZFP95 Zinc finger protein 95 homolog (mouse) (ZFP95). transcript variant 1 0.02 1.5
ZNF587 Zinc finger protein 587 (ZNF587) transcript variant 1 0.025 2.8
RGS2 Regulator of G-protein signalling 2. 24kDa (RGS2) 0.03 4.8
CR2 CR2/CD21/C3d/Epstein-Barr virus receptor mRNA. complete cds. [M26004] 0.034 2.5
DNAJA1 DnaJ (Hsp40) homolog. subfamily A. member 1 (DNAJA1) 0.034 3.3
HSPA1L Heat shock 70kDa protein 1-like (HSPA1L) 0.034 3.1
MICB MHC class I polypeptide-related sequence B (MICB) 0.034 1.4
RACGAP1 Rac GTPase activating protein 1 (RACGAP1) 0.034 2.1
ZNF473 Zinc finger protein 473 (ZNF473). transcript variant 1 0.034 1.7
DNAJB12 DnaJ (Hsp40) homolog. subfamily B. member 12 (DNAJB12). transcript variant 1 0.035 1.6
HSP90AA1 Heat shock protein 90kDa alpha (cytosolic). class A member 1 (HSP90AA1) transcript variant 2 0.045 5.3
PPARBP PPAR binding protein. mRNA (cDNA clone IMAGE:4822636). complete cds. [BC060758] 0.045 1.7
CCDC12 Coiled-coil domain containing 12 (CCDC12) 0.046 1.8
HSPA4L Heat shock 70kDa protein 4-like (HSPA4L) 0.046 3.6
15 Genes down-regulated following 17AAG treatment
Gene name Description FDR Fold Change
PLK3 Polo-like kinase 3 (Drosophila) (PLK3) 0.025 5.8
TMEM129 Transmembrane protein 129 (TMEM129) 0.027 2.2
IER3 Immediate early response 3 (IER3). transcript variant short 0.032 8.7
CCND1 Cyclin D1 (CCND1) 0.034 5.5
JUNB Jun B proto-oncogene (JUNB) 0.034 5
TSEN2 tRNA splicing endonuclease 2 homolog (S. cerevisiae) (TSEN2) 0.034 2.8
CCDC85B Coiled-coil domain containing 85B (CCDC85B) 0.035 2.3
WDR4 WD repeat domain 4 (WDR4). transcript variant 2 0.035 2.5
RFC4 Replication factor C (activator 1) 4. 37kDa (RFC4). transcript variant 1 0.044 2.2
PYCRL Pyrroline-5-carboxylate reductase-like (PYCRL) 0.045 2.9
SHMT2 Serine hydroxymethyltransferase 2 (mitochondrial) (SHMT2) 0.045 1.7
C6orf203 Chromosome 6 open reading frame 203 (C6orf203) 0.046 2.2
MAN1B1 Mannosidase. alpha. class 1B. member 1 (MAN1B1) 0.046 2.2
NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor. alpha (NFKBIA) 0.047 4.2
SFT2D3 SFT2 domain containing 3 (SFT2D3) 0.047 1.9
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To validate and investigate the significance of the
obtained molecular signature of 17AAG response, a
breast tumor biopsy from a patient with breast cancer
was grown in vitro and treated with the same concentra-
tion used for tumor cell lines for 24 h and 48 h. Simi-
larly to what was seen in cell lines [31], 17AAG
produced in these primary tumor cells a growth inhibi-
tory effect, with an arrest in G2/M phase of the cell
cycle (Figure 3). Then, changes in the expression of a
group of seven genes from the signature (HSP90,
HSPA8, DNAJA1, CHORDC1, DEDD2, HSPA4L and
MICB) were assessed by QT-PCR comparing with
untreated cells. Significantly all these genes were con-
firmed to be 17AAG-responsive genes, also in this pri-
mary tumor.
Transcriptional changes in HSP90 client proteins
The cellular response to 17AAG has a complex nature
with effects including protein and transcriptional
changes [25]. As the treatment with 17AAG has a global
effect in the cell through depletion of client proteins, we
were interested in analysing the subsequent changes
induced by HSP90 inhibition at transcription level. We
characterized the profile of transcriptional changes of
the list of 168 well reported Hsp90 client proteins and
interactors available on the Picard lab home page http://
www.picard.ch/DP/DPhome.html. Since expression of
HSP90 client proteins vary according to cell type, we
have presented the data of HSP90 interactors’ expres-
sion as differences in expression in treated cell lines ver-
sus their corresponding untreated cells. This analysis
revealed that each cell line has an individual pattern of
Hsp90 interactors’ changes (Figure 4A). As we expected,
variations in the expression levels of genes coding for
client proteins were much lower in resistant cell lines
comparing to the sensitive ones (Figure 4A), suggesting
that transcriptional changes of at least some client pro-
teins could be taken into account to measure drug
effectiveness.
To identify crucial differentially expressed HSP90 cli-
ents in each cell line, expression changes of >2 fold after
treatment were obtained. Indeed, the sensitive cell lines
showed a much higher number of HSP90 clients that
differ following treatment, compared to the resistant cell
lines. By selecting HSP90 interactors that change >2 fold
a tb o t ht i m ep o i n t s ,2 4ha n d4 8hf o l l o w i n g1 7 A A G ,
Hs578T cells showed 35 genes, MCF-7 showed 9 genes;
MDA-MB-157 showed 20 genes; MDA-MB-436 showed
13 genes; HCC1937 showed 17 genes and UACC3199
showed 9 genes (Figure 4B), while the resistant cell
lines, T47 D showed only 3 genes and in MDA-MB-231
only 2 genes changed. Moreover, there were only two
HSP90 interactors commonly upregulated in all the sen-
sitive cell lines: HSPA1A (HSP72), the inducible isoform
of HSP70, and CHORDC1.I n t e r e s t i n g l y ,t h er e s i s t a n t
cell line MDA-MB-231 showed exactly these two genes
HSPA1A and CHORDC1 upregulated at both time
points with no other HSP90 interactor significantly
changing its expression. Upregulation of HSPA1A was
detected also in T47 D resistant cells only after 48 h
post treatment.
In addition to HSPA1A and CHORDC1, other client
protein transcripts expression such as ASHA1 and
Figure 3 Effect of HSP90 inhibition by 17AAG in a biopsy from a breast cancer patient. A) Cell cycle analysis in untreated cells and cells
treated with 17AAG for 24 H and 48 H, exhibiting G2/M arrest at both time points. B) Validation of a group of genes from the signature of
response to 17AAG in the primary tumor cells. All these genes showed increased expression after treatment >2fold at 24 H or 48 H, as occurred
in the sensitive cell lines.
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with the treatment in at least four of the six cell lines
(Figure 4B).
Signaling Pathways related to resistance to 17AAG
It is well established that a major factor in resistance to
17-AAG is expression/activity of DT-diaphorase
(NQO1), [34,35]. The resistant cell line, MDA-MB-231,
has very low level of NQO1 [34], and it is likely to be
the main cause of 17AAG resistance in this cells. In
contrary, the other resistant cell line T47 D has higher
levels of NQO1 and may have another, independent
mode of resistance to 17AAG. Regardless of the intrinsic
mode of resistance in the two cell lines, we investigate
genes and pathways differentially modulated in respon-
sive and resistant cells following treatment.
Differential expression profiling between resistant and
sensitive cell lines after treatment was performed. As
expected, large differences were found, with more than
1500 genes significantly changing (data not shown).
Many of these differences could be attributed to the fact
that sensitive treated cells represent arrested cells, while
resistant cells are proliferating cells. In fact, significant
number of these genes was involved in cellular
metabolism.
Then, we tried to find whether there were significant
signaling pathways that could be differentially expressed
between treated sensitive and resistant cells. In order to
obtain significant pathways, gene set enrichment analysis
(GSEA) was performed. Because of the small number of
samples this analysis did not show any pathways asso-
ciated with 17AAG resistance with a FDR < 0.05. Even
though the three top pathways more associated to
17AAG resistance included CDMAC pathway (FDR =
0.157), NF-B pathway (FDR = 0.205) and ATM path-
way (FDR = 0.246) (See Additional file 1: Supplemental
Table S3, for a list of the top 10 pathways related to
17AAG resistant cells).
Additionally to the in silico pathway analysis, to look
for differentially activated pathways following 17AAG
treatment we have applied transcription factor-respon-
sive luciferase reporter assays to resistant (T47 D,
Figure 4 Transcriptional changes of HSP90 clients. A) Heatmap representing the differences in the mRNA expression found in the list of
known HSP90 clients and interactors in treated breast cancer cell lines (increments over untreated cells in red, reductions in blue). Weaker
variations in resistant cell lines are shown. B) Significant HSP90 client transcriptional changes in individual cell lines following 17AAG treatment.
Genes for which mRNAs exhibited over 2-fold increase or reduction are shown for the different cell lines. Stars indicate genes commonly
changing at least in four of the six cell lines.
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Page 8 of 13Figure 5 Differential signaling pathway activation in resistant and sensitive breast cancer cells upon treatment with 17AAG.
Transfections were carried out in the sensitive (MCF-7 and Hs578T) and resistant (MDA MB 231 and T47D), cells with the reporter constructs for
the typical cancer biology pathways: NOTCH, WNT, TGFb, P53, cell cycle, MYC/MAX, NF-B, MAPK/ERK, MAPK/JNK and HIF, followed by 17AAG or
DMSO treatment. Dual-luciferase assay was performed, and promoter activity values are expressed as arbitrary units using a Renilla reporter for
internal normalization. The experiment performed itself in triplicates was repeated at least twice of each cell line studied. The error bars
represent standard deviation. Pathways significantly (p-value < 0.05) repressed or activated are marked with a star.
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Page 9 of 13MDA-MB-231) and two sensitive cell lines (Hs578T,
MCF-7). The latter quantitatively assesses the signal
transduction pathway changes by measuring the activ-
ities of downstream transcription factors. By this
method we evaluated activation of ten different cancer
related pathways such as NOTCH, WNT, TGFb,P 5 3 ,
cell cycle, MYC/MAX, NF-B, MAPK/ERK, MAPK/JNK
and HIF1.
Interestingly, the results revealed that NF-Ba n d
M A P K / J N Kp a t h w a yw e r ef o u n dsignificantly activated
in both resistant compared to the sensitive cell lines
(Figure 5). Although below statistical significance, GSEA
revealed NF-B as one of the most relevant pathways
associated to 17AAG resistance. The increased activity
of the NF-B, may indicate that this pathway plays an
important role in cell survival upon treatment. Addition-
ally, MAPK pathways could have also some role in the
resistance to 17AAG, as MAPK/JNK was significantly
activated in both resistant T47 D and MDA-MB-231
cell lines, and the MAPK/ERK was induced in T47 D.
Cell cycle pathway was significantly activated only in
MDA-MB-231 resistant cell line, what may reflect the
higher proliferation status of these cells. Sensitive MCF-
7 cells showed a critical reduction in the activity of all
of the pathways, which correlate with the stop in prolif-
eration and death induced after the treatment (Figure
5). The other sensitive cell line, Hs578T also showed
inhibition of most of the pathways except NOTCH,
TGF and Hypoxia pathway.
Discussion
In an attempt to identify detailed molecular mechanisms
of drug response and resistance to treatment with
17AAG we performed gene expression profiling of eight
breast cancer cell lines treated with the drug. Although
there are many studies analyzing the molecular effect of
HSP90 inhibition, global expression changes after
17AAG in breast cancer have not been analyzed in-
depth. In this study we examined the expression
changes in the sensitive (MCF-7, MDA-MB-157,
Hs578T, UACC3199, HCC1937, MDA-MB-436) and
two resistant (MDA-MB-231, T47D) breast cancer cell
lines to the HSP90 inhibitor, 17AAG.
Gene expression profiling after 17AAG, showed differ-
ent number of 17AAG responsive genes associated to the
different cell lines. As HSP90 inhibition results in degra-
dation of client proteins, it is possible that intrinsic differ-
ences in the abundance of HSP90 clients in the cells
cause subsequent transcriptional changes in a cell line
dependent manner. Although it was clear that HSP90
inhibition produced cell line dependent changes we
could not associate them to the fact that these cell lines
belong to different molecular breast cancer subtypes.
Since one of the resistant cell lines, MDA-MB-231,
is reported to be basal B and the other, T47 D, as
luminal, and the rest of the sensitive cell lines being
all basal B except for MCF7 (luminal) and HCC 1937
(basal A) [36] it is likely that sensitivity to 17AAG is
not connected to known breast cancer subtypes.
However, there were a group of genes commonly
regulated in all sensitive cell lines upon treatment. We
have identified a breast cancer associated molecular sig-
nature of response to 17AAG, consisting of 35 17AAG-
responsive genes. This gene signature of 17AAG
response included, similar as previously reported in
other studies [24-26], members of the chaperon com-
plex, HSP90 itself and HSP70 (HSPA8). These changes
were identified in a study done in an ovarian cancer cell
line as likely on-target effects of the drug, which are
induced as a direct consequence of HSP90 inhibition
[25]. Importantly, HSP70 isoforms have been used as
pharmacodynamic end point in clinical trials [27]. In
addition to these chaperons, we also identified up-regu-
lation of other members of heat shock response family
such as HSPA4L, HSPA1L, HSP40 (DNAJA1 and
DNAJB12) and in CHORDC1, another HSP90 binding
protein. Interestingly, we found transcriptional induction
of HSP90, HSP70 (HSPA8) and HSPA4L in one of the
resistant cell lines analyzed, MDA-MB-231. Moreover,
HSC70/HSPA8 and HSP72 induction was confirmed by
western blot in these cells. The up-regulation after treat-
ment of HSP90 and HSP70 (both HSC70 and HSP72)
might suggest that HSP90 is inhibited at 500 nM
17AAG in both sensitive and MDA-MB-231 resistant
cell line. Yet, the resistance in the MDA-MB-231cell
lines might be caused by very low levels of NQO1, as
reported previously [37]. HSC70 and HSP72 also have
an antiapoptotic role [38], so their induction in MDA-
MB-231 might also contribute to the 17AAG resistance
in these cells. The other resistant T47 D cells seem not
to show the induction of Hsp70 isoforms following
treatment what could suggest lack of HSP90 target inhi-
bition by 17AAG. Interestingly, T47 D cells have some
expression of NQO1 and probably an alternative
mechanism of resistance.
The analysis of a number of HSP70 isoforms by immu-
noblotting revealed, in addition to induction of HSC70
a n dH S P 7 2 ,t h a ts o m eo t h e rH S P 7 0i s o f o r m sw e r ea l s o
induced by 17AAG. Up-regulation of HSPA1L and
HSPA2 were found in sensitive cells following exposure to
17AAG. However, they showed lack of induction in resis-
tant MDA-MB-231 cells. We suggest that HSPA1L and
HSPA2 could represent potential biomarkers to follow up
the effectiveness of 17AAG in breast cancer, although the
mechanism underlying this effect is still unclear.
Other genes from the signature also exhibiting
increased expression in response to 17AAG were Rac
GTP-ase activating protein (RACGAP1), ubiquitin
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(ZNF473, ZNF587) and MHC class I antigen (MICB).
These data are in line with previous work done on
17AAG treated ovarian cancer cell lines [25]. Addition-
ally, in a recent microarray study of novel HSP90 inhibi-
tor (IPI-504) in pancreatic cancer, Song and colleagues
[26] identified similar class of up-regulated genes follow-
ing treatment along with GTPase activating proteins,
zinc finger proteins, heat shock proteins and ribosomal
proteins.
There were also genes with decreased expression fol-
lowing HSP90 inhibition by 17AAG. Some of them
clearly represent cell cycle regulators (CCND1, PLK3)
and important proliferation signaling pathways media-
tors (JUNB, NFKBIA). The decreased expression of
them might be a consequence of cell cycle arrest pro-
duced after 17AAG.
The fact that the expression changes seen in the pri-
mary tumor sample after treatment with 17AAG
resembled the changes in cell lines, suggests that this set
of genes would constitute a robust signature of response
in breast cancer. Further studies in additional tumor
biopsies are required to better establish the value of the
biomarkers identified in this study.
S i n c ee f f e c t so f1 7 A A Ga r ed r i v e nb yH S P 9 0c l i e n t
proteins degradation, we were interested in studying
whether protein depletion also results in transcriptional
changes of known client proteins following treatment.
Changes in the mRNA levels of a number of client pro-
teins were evident in cell lines responsive to 17AAG,
while resistant cell lines demonstrated insignificant var-
iations in transcriptional levels of HSP90 interactors.
This observation suggests that the use of transcriptional
changes of HSP90 client proteins may facilitate the
selection of potentially responsive patients to 17AAG
therapy. It is known that client proteins are variable in
different types of tumor [10]. It is reasonable then, to
find cell line specific transcriptional changes profiles in
the 17AAG sensitive cell lines. This finding could be of
interest in order to define, in further studies, key client
proteins for specific tumor subtypes, with potential clini-
cal significance. In addition, consistently up or down-
regulated HSP90 client transcripts following treatment
were identified shared by some of the cell lines analyzed
(AHSA1, CCNB1, IRAK1),t h a tc o u l dr e p r e s e n ti m p o r -
tant HSP90 clients in breast cancer. It is clear that bio-
logical processes are regulated not only at
transcriptional level, but also protein levels or posttran-
scriptional modifications of proteins are important when
analyzing the effects of HSP90 inhibitors. However,
mRNA changes could be helpful in order to evaluate
the effect of the drug in clinical samples.
Mechanisms of resistance to 17AAG remain largely
unknown. We analyze global expression changes after
17AAG occurring in resistant cells, to define genes or
pathways commonly involved in insensitivity to this
drug. The identification of pathways in relation to
17AAG resistance would be important to develop in
future candidate treatments to be used in combination
with 17AAG to induce growth inhibitory effects in the
insensitive cell lines. Functional studies with the path-
way-focused reporter assays shown significant up-regula-
tion of NF-B pathway in resistant cells after exposure
to 17AAG. It is interesting that GSEA also showed NF-
B pathway as potentially involved in resistance to
17AAG. In addition, there are two other resistance asso-
ciated pathways in the top-ten list that were related to
inflammation/immune response (NTHI_PATHWAY
and INFLAM_PATHWAY) (Additional file 1: Supple-
mental Table S3). Thus it is possible that resistant
breast cancer cell lines make use of the inflammation/
immune response machinery to evade cell cycle arrest
or apoptosis after 17AAG treatment. NF-B activation
was already observed after treatment with cancer che-
motherapeutic agents such as gemcitabine [39-41],
thereby inducing resistance to apoptosis which results in
poor clinical outcome. NF-B is a ubiquitously
expressed transcription factor that is involved in a wide
spectrum of cellular functions including cell cycle con-
trol, stress adaptation, inflammation and control of
apoptosis [42]. Activation of NF-B has been implicated
in the development of a number of human malignancies,
and it appears to be important for the survival of cancer
cells, as well as the conferring of more aggressive tumor
phenotype and resistance to drug therapies [43-46].
Moreover, high basal levels of NF-kB have been related
with resistance to gemcitabine in pancreatic carcinoma
cell lines [41,45]. The finding of NF-kB pathway activa-
tion after 17AAG treatment significantly associated to
resistant cell lines suggests that simultaneous use of
anti-tumor agents that block NF-B activity together
with HSP90 inhibitors may have a greater therapeutic
value. MAPK/JNK, and also MAPK/ERK pathway were
activated in the resistance cell lines, suggesting these
pathways may be important for survival of cells after
17AAG treatment.
In summary, in this study we have established a 35
gene-based molecular signature of response to 17AAG
in breast cancer, which revealed novel pharmacody-
namic markers of drug response. Secondly, we have
defined transcriptional changes in known HSP90 client
proteins, which may be useful to monitor drug efficacy
and finally, we have identified signaling pathways differ-
entially activated following 17AAG in resistant cell lines.
Conclusions
T h i ss t u d yc o n f i r m sg e n ee x p r e s s i o np r o f i l i n ga sau s e -
ful tool in further understand molecular response to
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markers. By analyzing gene expression changes
induced by 17AAG in breast cancer cells we have
identified a novel breast cancer associated molecular
signature of response to 17AAG, consisting of 35
17AAG-responsive genes which might be potential bio-
markers of sensitivity to evaluate clinical response.
Analysis of mRNA changes of known HSP90 clients
demonstrated cell line specific patterns associated with
responsive cells, so this approach could be useful for
the follow up of treatment response and could facili-
tate the discovery of key clients. In addition, signaling
pathways associated with resistance to 17AAG were
found, such as induction in DNA-binding activity of
NF-B in resistant cells after treatment. The identifica-
tion of pathways associated to resistance would enable
the design of combined therapies to overcome 17AAG
resistance.
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